ADMA Biologics Q2 2024 GAAP EPS $0.13 Beats $0.07 Estimate, Sales $107.191M Beat $86.412M Estimate
Portfolio Pulse from Benzinga Newsdesk
ADMA Biologics reported Q2 2024 earnings per share of $0.13, significantly beating the analyst estimate of $0.07. The company also reported sales of $107.191 million, surpassing the estimate of $86.412 million. Both EPS and sales showed substantial year-over-year growth.
August 08, 2024 | 8:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ADMA Biologics reported Q2 2024 earnings per share of $0.13, significantly beating the analyst estimate of $0.07. The company also reported sales of $107.191 million, surpassing the estimate of $86.412 million. Both EPS and sales showed substantial year-over-year growth.
ADMA Biologics' strong earnings and sales performance, significantly beating analyst estimates, is likely to positively impact the stock price in the short term. The substantial year-over-year growth further supports a positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100